Melior Pharmaceuticals   Report issue

For profit Phase 2
Founded: Exton PA United States (2010)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2014
NCT02317796
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Melior Pharmaceuticals | Melior Pharmaceuticals I & Bukwang Pharm. Co., Ltd. | Melior Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

Tolimidone (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1